Allurion Technologies Inc. (ALUR)

NYSE: ALUR · Real-Time Price · USD
3.260
+0.140 (4.49%)
At close: Mar 27, 2025, 4:00 PM
3.200
-0.060 (-1.84%)
After-hours: Mar 27, 2025, 5:54 PM EST
4.49%
Market Cap 23.47M
Revenue (ttm) 32.11M
Net Income (ttm) -26.15M
Shares Out 7.20M
EPS (ttm) -11.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 458,629
Open 3.160
Previous Close 3.120
Day's Range 2.960 - 3.499
52-Week Range 2.150 - 98.750
Beta -0.63
Analysts Strong Buy
Price Target 22.83 (+600.31%)
Earnings Date Mar 26, 2025

About ALUR

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts. [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2009
Employees 504
Stock Exchange NYSE
Ticker Symbol ALUR
Full Company Profile

Financial Performance

In 2024, Allurion Technologies's revenue was $32.11 million, a decrease of -39.94% compared to the previous year's $53.47 million. Losses were -$26.15 million, -68.23% less than in 2023.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ALUR stock is "Strong Buy." The 12-month stock price forecast is $22.83, which is an increase of 600.31% from the latest price.

Price Target
$22.83
(600.31% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Allurion Technologies Inc. (ALUR) Q4 2024 Earnings Call Transcript

Allurion Technologies Inc. (NYSE:ALUR) Q4 2024 Earnings Conference Call March 26, 2025 8:30 AM ET Company Participants Mike Cavanaugh - Investor Relations Shantanu Gaur - Founder and Chief Executive ...

1 day ago - Seeking Alpha

Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the f...

1 day ago - Business Wire

Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced initial results on the combinat...

7 days ago - Business Wire

Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will report financial r...

15 days ago - Business Wire

Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received two Issue ...

23 days ago - Business Wire

Allurion to Participate in Upcoming Investor Conferences

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating i...

4 weeks ago - Business Wire

Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has closed its previous...

5 weeks ago - Business Wire

Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive sec...

5 weeks ago - Business Wire

Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a cli...

5 weeks ago - Business Wire

Allurion Relaunches in France

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it is relaunching the Allu...

6 weeks ago - Business Wire

Allurion Technologies Shares Are Up Today: What's Going On?

Allurion Technologies ALUR shares are moving higher Friday, potentially in response to the company's Thursday announcement of a planned clinical study to evaluate the combination of its Allurion Progr...

2 months ago - Benzinga

Allurion Stock Triples on Plan to Test Gastric Balloon With Obesity Drugs

Shares of Allurion Technologies (ALUR) tripled Friday as the maker of the Allurion Gastric Balloon weight-loss device looked to take advantage of the booming obesity drug market.

2 months ago - Investopedia

Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive sec...

2 months ago - Business Wire

Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical stud...

2 months ago - Business Wire

Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received an Issue Notificatio...

2 months ago - Business Wire

Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a subscription a...

2 months ago - Business Wire

Allurion Announces Positive Topline Results From AUDACITY Trial

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced topline results from the AUDACITY Food & Drug Administration (FDA) pivo...

2 months ago - Business Wire

Allurion Technologies, Inc. Announces Reverse Stock Split

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that its Board of Directors has determine...

3 months ago - Business Wire

Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it received an Acceptance Letter from the List...

4 months ago - Business Wire

Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the launch of AllurionMeds, a unique offering to pa...

4 months ago - Business Wire

Allurion Technologies Inc. (ALUR) Q3 2024 Earnings Call Transcript

Allurion Technologies Inc. (NYSE:ALUR) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Mike Cavanaugh – Investor Relations Shantanu Gaur – Founder and Chief Executi...

4 months ago - Seeking Alpha

Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the third quart...

4 months ago - Business Wire

Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society's Annual Conference

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the presentation of two abstracts at Obesity Week 2...

5 months ago - Business Wire

Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will report financial results for...

5 months ago - Business Wire

Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the submission of the first three modules of its pr...

5 months ago - Business Wire